Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

Trial ID or NCT#



recruiting iconRECRUITING


The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone marrow Transplantation are enrolling patients into a research study to determine if donor stem cells given after a living related one Haplotype match kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn.

Official Title

Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation

Eligibility Criteria

Ages Eligible for Study: 18 Years to 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. All consenting adults who are 18 to 60 years, living donor transplant candidates and have a haplotype related living donor or > 2 HLA antigen matched, unrelated, living donor (including at least one HLA-DR antigen match plus at least one antigen match of either HLA-A or HLA-B). 2. Patients who agree to participate in the study and sign an Informed Consent. 3. Patients who have no known contraindication to administration of rabbit ATG or radiation. 4. Males and females of reproductive potential who agree to practice a reliable form of contraception for at least 24 months post-transplant. 5. ABO compatible.
Exclusion Criteria:
  1. 1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins. 2. History of malignancy with the exception of non-melanoma skin malignancies. 3. Pregnant women or nursing mothers. 4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection. 5. Seronegative for Epstein-Barr virus, if donor is seropositive. 6. Leukopenia (with a white blood cell count < 3000/mm3) or thrombocytopenia (with a platelet count < 100,000/mm3). 7. Panel Reactive Antibody greater than 80% or demonstration of donor specific antibody (DSA). 8. Prior organ transplantation. 9. High risk of primary kidney disease recurrence (e.g atypical HUS). However, patients with primary FSGS will not be excluded.


Stephan Busque
Stephan Busque
Transplant surgeon, Kidney transplant surgeon, Pancreas transplant surgeon
Professor of Surgery (Abdominal Transplantation)
Robert Lowsky
Robert Lowsky
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Samuel Strober
Marc L. Melcher
Marc L. Melcher
Transplant surgeon, Liver transplant surgeon, Kidney transplant surgeon, Hepatobiliary surgeon, Dialysis access surgeon
Professor of Surgery (Abdominal Transplantation)
Richard Hoppe
Richard Hoppe
Radiation oncologist
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
John Scandling
John Scandling
Kidney transplant specialist, Tolerance induction protocol specialist
Professor of Medicine (Nephrology) at the Stanford University Medical Center, Emeritus
Judith Shizuru
Judith Shizuru
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist, Hematologist-Oncologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)

Contact us to find out if this trial is right for you.


Asha Shori, CCRP